After the Alcon separation was announced, Moody’s downgraded Novartis’ rating, with the agency suggesting the move increases the company’s reliance on riskier, innovative medicines development.

Novartis and eyecare spinout Alcon have agreed to settle bribery charges ... to boost prescriptions of Lucentis (ranibizumab), the company’s drug for wet age-related macular degeneration ...

The eye-care company Alcon Research has entered into licensing ... such as ranibizumab (Lucentis; Genentech/Novartis), which inhibit the growth of abnormal new blood vessels and bleeding in ...

Alcon's product launch lineup, considered one of the best since its spin-off from Novartis (LON:0QLR) (SIX:NOVN), is expected to significantly contribute to its performance. The company has ...

Novartis' solid late-stage pipeline should propel long-term growth. The company should launch several ... The recent decisions to spin off the Alcon (ophthalmology business) and Sandoz (generic ...

Founded in 1945, Alcon was first acquired by a Swiss subsidiary of Nestlé S.A. and began operating as a wholly owned subsidiary of Nestlé until 2002. From Mar 20, 2002 until its 2011-merger into ...